Bunnage Mark E.'s Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Feb 19, 2026
- Accession no.
- 0000875320-26-000088
- Filed
- Feb 19, 2026
- Trade date
- Feb 17-18, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions. Open-market sales total $1.75M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bunnage Mark E.CIK 0002100735 | Officer (EVP, Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | Common Stock | AGrant or awardAcquired | +2,584 | $0.00 | $0 | 13,215 | Direct | |
| Feb 17, 2026 | Common Stock | FTax withholdingDisposed | −1,110 | $483.75 | −$536,962.5 | 12,105 | Direct | |
| Feb 17, 2026 | Common Stock | SSaleDisposed | −2,437 | $489.46 | −$1,192,814.02 | 9,668 | Direct | |
| Feb 18, 2026 | Common Stock | SSaleDisposed | −1,182 | $473.68 | −$559,889.76 | 8,486 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.